Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference


Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.

Details of the event are as follows:

Panel: "Off-the-Shelf CART ? Let's Talk Lupus and Oncology"
Date: Monday, April 15, 2024
Time: 3:00 p.m. ET

The Adicet Bio team will be available for one-on-one meetings throughout the conference. Please contact your sales representative at Canaccord Genuity to register for a meeting with the company.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.


These press releases may also interest you

at 03:44
21st.BIO unveils a new pilot plant facility to accelerate impact of biotech innovations globally
21st.BIO unveiled a new pilot plant facility in its Danish...

at 03:05
Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global...

at 03:05
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 ? A Potent Inhibitor of Cancer Metabolism
Lantern Pharma Inc. , a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of...

at 03:00
Red light therapy for repairing spinal cord injury passes milestone
Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light....

at 03:00
World Lupus Federation Global Survey Finds 91% of People with Lupus Report Using Oral Steroids to Treat Lupus
A recent global survey conducted by the World Lupus Federation reported that 91% of survey respondents were taking or have taken oral steroids to treat their lupus. Over 7,700 people living with lupus from more than 100 countries participated in the...

at 02:11
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
Calliditas Therapeutics AB ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and...

More news about Health...


News published on and distributed by: